The Aquila Study Strongly Supports the Benefit of Early Intervention with Daratumumab Monotherapy in Patients with High-Risk Smoldering Multiple Myeloma

Daratumumab monotherapy demonstrates a clinically meaningful and significant benefit in preventing or delaying progression to active multiple myeloma in patients with high-risk smoldering multiple myeloma. According to Fredrik Schjesvold, Oslo Myeloma Center, the Aquila study was the most interesting trial for multiple myeloma during ASH 2024.